The Hsp70–Bim dimer is a specific target activated by BCR–ABL in chronic myeloid leukemia that can lead to TKI resistance by stabilizing downstream kinases such as AKT and Raf-1. Here, BCL2L11 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.